title: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
abstract: BACKGROUND
  To evaluate the activity and toxicity of docetaxel in patients with metastatic esophageal cancer.
  
  
  METHODS
  Eligible patients had histologically confirmed carcinoma of the esophagus with measurable metastatic sites according to Response Evaluation Criteria in Solid Tumors (RECIST). Patients were either chemotherapy-naïve or previously treated with one regimen of chemotherapy. Docetaxel 70 mg/m(2) was administered intravenously over 1-2 h, every 21 days.
  
  
  RESULTS
  Of 52 patients enrolled in this study, three were excluded because they did not receive docetaxel due to worsening condition after enrollment. Thirty-six patients had received prior platinum-based chemotherapy. The majority of patients (94%) had squamous cell carcinoma. Ten of 49 evaluable patients [20%; 95% confidence interval (CI) 10-34%] showed a partial response. Of the 10 partial responses, six patients had received prior platinum-based chemotherapy. Grade 3 or 4 neutropenia was noted in 43 of 49 patients (88%), and nine of 49 patients (18%) developed febrile neutropenia. Twenty-eight of 49 patients (57%) required lenograstim. Grade 3 anorexia and fatigue occurred in nine (18%) and six (12%) patients, respectively. Median survival time was 8.1 months (95% CI 6.6-11.3) and the 1-year survival rate was 35% (95% CI 21-48%).
  
  
  CONCLUSIONS
  Docetaxel as a single agent is effective in esophageal cancer, but careful management of neutropenia is needed.
authors.affiliation: Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan. kmuro@ncc.go.jp
authors.forename: K
authors.initials: K
authors.lastname: Muro
authors.forename: T
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: A
authors.initials: A
authors.lastname: Ohtsu
authors.forename: N
authors.initials: N
authors.lastname: Boku
authors.forename: K
authors.initials: K
authors.lastname: Chin
authors.forename: I
authors.initials: I
authors.lastname: Hyodo
authors.forename: H
authors.initials: H
authors.lastname: Fujita
authors.forename: W
authors.initials: W
authors.lastname: Takiyama
authors.forename: T
authors.initials: T
authors.lastname: Ohtsu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D016019:Survival Analysis; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel